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The objectives here are to provide a systematic review of the current evidence concerning the use of Chinese herbs in the treatment
of Alzheimer’s disease (AD) and to understand their mechanisms of action with respect to the pathophysiology of the disease. AD,
characterized microscopically by deposition of amyloid plaques and formation of neuroﬁbrillary tangles in the brain, has become
the most common cause of senile dementia. The limitations of western medications have led us to explore herbal medicine.
In particular, many Chinese herbs have demonstrated some interesting therapeutic properties. The following databases were
searched from their inception: MEDLINE (PUBMED), ALT HEALTH WATCH (EBSCO), CINAH and Cochrane Central. Only
single Chinese herbs are included. Two reviewers independently extracted the data and performed quality assessment. The quality
assessment of a clinical trial is based on the Jadad criteria. Seven Chinese herbs and six randomized controlled clinical trials were
identiﬁed under the predeﬁned criteria. Ginkgo biloba, Huperzine A (Lycopodium serratum) and Ginseng have been assessed for
their clinical eﬃcacy with limited favorable evidence. No serious adverse events were reported. Chinese herbs show promise in
the treatment of AD in terms of their cognitive beneﬁts and more importantly, their mechanisms of action that deal with the
fundamental pathophysiology of the disease. However, the current evidence in support of their use is inconclusive or inadequate.
Future research should place emphasis on herbs that can treat the root of the disease.
1.Introduction
Alzheimer’sdisease(AD),ﬁrstdescribedbyGermanpsychia-
tristAloisAlzheimerin1906,isaprogressiveneurodegenera-
tive disease characterized by cognitive deterioration together
with behavioral disturbances and declining activities of daily
living [1]. AD is the most common cause of senile dementia
[2] with a prevalence estimated to be 1.6% in the USA
[3]. The rate is expected to increase over time as the
aging population grows inasmuch as more than 80% of AD
patients are 65 years or older.
Microscopically, AD is characterized by amyloid plaques
and neuroﬁbrillary tangles [4]. Amyloid plaques are dense
deposits of amyloid-beta (Aβ) protein. Accumulation of
aggregated amyloid ﬁbrils, which are believed to be neuro-
toxic, causes loss of neurons and synapses in the cerebral
cortex and certain subcortical regions and results in gross
atrophy of the aﬀected areas [5]. However, deposition of
amyloid plaques does not correlate well with neuron loss
[6]. In a recent clinical trial, an experimental vaccine
was found to clear the amyloid plaques, but it did not
have any signiﬁcant eﬀect on dementia [7], suggesting that
neuroﬁbrillarytanglescouldplayamoreimportantrolethan
amyloid plaques in the pathophysiology of AD.
The short-term memory dysfunction in AD has been
related to reduction in the activity of the cholinergic neurons
[8]. Among the four medications currently approved by the
US FDA (Food and Drug Administration) for treating the
cognitive deﬁciency of AD, three are acetylcholinesterase
inhibitors (donepezil, galantamine and rivastigmine), which
increase cholinergic activity. However, the eﬃcacy of
cholinesterase inhibitors for the treatment of AD is not
supported by a high-quality large-scale randomized double-
blindclinicaltrial[9].Approachesbasedontheuseofantiox-
idants, anti-inﬂammatory drugs, vitamin E and estrogen
remain controversial [10].
We have identiﬁed two systematic reviews in the liter-
ature concerning the eﬃcacy of herbal medicine for AD
[11, 12]. The ﬁrst systematic review included four clinical
studies, among which western herbs were examined in two2 Evidence-Based Complementary and Alternative Medicine
studies and Chinese herbs in the other two. The second
systematic review published in 2008 included 16 clinical
studies, among which western herbs were examined in two
studies, Japanese herbs in one study and Chinese herbs in the
rest of studies (13 studies). The results suggest that Chinese
herbal medicine represents a promising area in the future
treatment of AD. Unfortunately, Chinese herbal remedies
that have undergone clinical trials are mostly in the form
of herbal formulas rather than single herbs. It would be
diﬃcult to identify and validate the eﬀective ingredients in
an herbal formula that demonstrates clinical eﬃcacy. Thus
our systematic review is focused on single Chinese herbs
that have eﬀects on the development and progression of
AD according to experimental and clinical evidence. This
review excludes western herbs such as Salvia oﬃcinalis and
Melissa oﬃcinalis that have demonstrated clinical beneﬁts to
AD patients.
2. Methods
The following computerized databases were searched from
their inception to December 2008: MEDLINE (PUBMED),
ALT HEALTH WATCH (EBSCO), CINAHL and Cochrane
Central. Text word search of titles and abstracts was con-
ducted using the following entries in various conjunction or
disjunction: Alzheimer’s Disease, Chinese, herbs, and herbal
medicine. Only articles originally written in English or
translated into English were considered.
Each study included in this review satisﬁed the following
criteria: (i) the disease studied was AD and (ii) the herb
studied was a Chinese herb. The exclusion criteria consisted
of (i) the study was a clinical trial but it was not a
randomized controlled trial (RCT), (ii) the herb studied was
an herbal formula (i.e., neither a single herb nor a single
herbal compound), (iii) the diseased population studied
included the dementia of non-AD type (e.g., dementia due
to brain ischemia or infarct) and (iv) the herb concerned was
not a Chinese herb. Two reviewers independently extracted
the data and performed quality assessment. The quality
assessment in this review is based on the validated Jadad
criteria, which was devised for grading the quality of RCTs
[13].
3. Results
Our review has identiﬁed seven Chinese herbs that have
been studied for their potential beneﬁts in AD treatment.
Out of these seven herbs, Ginkgo biloba, Huperzine A and
Ginseng have been assessed for clinical eﬃcacy separately
in six RCTs (Table 1). The mechanisms of action of each
herb are shown in Table 2. The pathological stages of AD are
drawn in Figure 1 and the pathophysiological target site of
each Chinese herb is shown in Figure 2.
3.1. Ginkgo biloba. Ginkgo biloba has been used as Chinese
herbal medicine to treat a variety of health disorders
for centuries. Ginkgo seed is used as an astringent for
problemslikeasthma,chronicbronchitis,spermatorrheaand
leukorrhea. Ginkgo leaf is used for vascular insuﬃciency
such as coronary heart disease. G. biloba exhibits several
interesting properties that make it a promising herbal
candidate for the treatment of AD [20] .T h eh e r bi sa
well-known anti-oxidant and can protect the brain from
Aβ-induced oxidative damage. In addition, G. biloba can
inhibit the Aβ ﬁbril formation, the toxicity of Aβ-derived
neurotoxins known as Amyloid-beta derived diﬀusible lig-
ands (ADDLs), and Aβ-induced apoptosis. The herb also
shifts the metabolism of amyloid precursor protein (APP) in
favor of the non-amyloidogenic pathway. Furthermore, the
herb can modulate brain cholinergic transmission, increase
brain cholinergic activity, and normalize the acetylcholine
receptorsinthehippocampusarea[10].TheG.bilobaextract
EGb 761 used in the clinical trials contained 22%–27%
of ﬂavonoids, 5%–7% terpene lactones and no more than
5ppm alkylphenols [15].
The clinical eﬃcacy of G. biloba extract EGb 761 was
assessed in a clinical study conducted by Maurer et al.
[14]. This study is a double-blind RCT. Twenty AD patients
aged 50–80 with mild to moderate dementia were recruited.
After excluding two patients, the remaining 18 patients were
randomly divided into the treatment and control groups.
Over a 3-month period, the treatment group received an oral
daily dose of 240mg EGb 761, whereas the control group
received a placebo. The primary outcome measure was SKT
(Syndrom-KurzTest),whichisashortcognitiveperformance
testforassessingmemoryandattention.Secondarymeasures
such as AD assessment scale (ADAS) and EEG were analyzed
qualitatively. The study conﬁrmed the eﬃcacy of EGb 761, as
measured by SKT, for the treatment of mildly to moderately
severe AD. In addition, EEG showed some improvement in
brain activity. However, the results based on the ADAS were
not statistically signiﬁcant, possibly due to the small sample
size.Thequalityofthisstudyisfair.Nosuﬃcientdetailswere
reported with respect to the procedures of randomization
and blinding as well as the tracking of dropouts in the
process. The validity of the study would also be weakened
by the small sample size.
Schneider et al. [15] conducted a large-scale double-
blind, multicenter RCT for determining the clinical eﬃcacy
of G. biloba extract EGb 761 in AD. Patients aged 60 years
or older with mild to moderate dementia of the AD type
for at least 6 months were recruited. Patients were excluded
from the trial if they had any other type of dementia or
central nerve system disorder or if they had taken anti-
dementia medications including cholinesterase inhibitors
within 6 weeks of study entry. A CT or MRI scan performed
within one-year of study entry and being consistent with
the diagnosis of AD was required at inclusion After initial
screening, 513 patients participated in the study and they
were randomly divided into three groups. Over a 26-week
period, 169 patients received an oral daily dose of 120mg,
170 patients an oral dose of 240mg and 174 patients took a
placebo. The primary outcome measures are ADAS-cog and
ADCS-CGIC. The results showed no statistically signiﬁcant
diﬀerences between the treatment and control groups, and
the eﬃcacy of G. biloba on AD remained inconclusive. The
high quality of this study is reﬂected by its large sampleEvidence-Based Complementary and Alternative Medicine 3
Table 1: The study design, herbal intervention, outcome measures, and results of RCTs concerning single Chinese herbs in the treatment of
AD.
Study Design Herb name Quality Rx N Cx N Outcome
measuresa Side eﬀects Results
Maurer et
al. [14]
Randomized,
double-blind,
placebo-
controlled,
parallel
G. biloba
(EGb761) 80mg
tid for 3 months
31 0 1 0 S K T No adverse
events
Rx > Placebo
(SKT) (P<. 05)
Schneider
et al. [15]
Randomized,
double-blind,
placebo-
controlled, parallel,
multi-center
G. biloba
(EGb761) 120mg
or 240mg per day
for 26 weeks
4 169 (120mg)
170 (240mg) 174 ADAS-cog,
ADCS-CGIC
Related serious
adverse events
(1% in 120mg
Gp and 2% in
240mg Gp)
Rx = Placebo
Mazza et
al. [16]
Randomized,
double-blind,
placebo-
controlled,
parallel
G. biloba
(EGb761) 160mg
per day for 24
weeks
52 5 2 5 b,2 6 c SKT MMSE
CGI
No adverse
events
(1)Rx =
Donepezil
(2) Rx >
Placebo (SKT,
CGI) (P<. 001)
(3) Rx =
Placebo
(MMSE)
Xu et al.
[17]
Randomized,
double-blind,
placebo-
controlled, parallel,
multi-center
Huperzine A
0.2mg b.i.d. for 8
weeks
35 0 5 3
Wechsler,
Hasegawa,
MMSE
No severe side
eﬀects
Rx > Placebo
(P<. 05)
Zhang et
al. [18]
Randomized,
double-blind,
placebo-
controlled, parallel,
multi-center
Huperzine A
0.4mg per day for
12 weeks
4 100 102 ADAS MMSE Ankle edema,
insomnia (3%)
Rx > Placebo
(P<. 001)
Heo et al.
[19]
Randomized,
non-blinding,
controlled, parallel
Ginseng 4.5g or
9.0g per day for
12 weeks
1 15 (9g)
15 (4.5g), 31 ADAS, MMSE,
CDR
Nausea, fever
(13%)
(1) Rx (9g) >Cx
(ADAS-cog,
CDR) (P<. 05)
(2) Rx = Cx
(MMSE)
Rx, Herbal treatment; Cx: Control intervention. Rx > Cx: The treatment is more eﬀective than the control intervention. Rx = Cx: No statistically signiﬁcant
diﬀerence between the treatment and control interventions.
aPrimary outcome measure; bDonepezil 5mg per day; cPlacebo.
size, the use of strict inclusion and exclusion criteria, sound
randomization and blinding techniques, and a detailed
dropout report. Therefore, this study would reasonably carry
more weight in its conclusion when compared with other
studies.
A double-blind RCT conducted by Mazza et al. was
aimed to compare G. biloba extract EGb 761 and a second-
generation cholinesterase inhibitor, donepezil, for their
eﬃcacy in the treatment of AD [16]. Patients aged 50–80
years with a mild to moderate degree of AD dementia were
recruited but patients with dementia of other etiologies were
excluded.Medicationswithcognitiveeﬀectswereprohibited.
In the study, 76 patients were randomized into three groups.
Over a 24-week period, 25 patients received an oral daily
dose of 160mg EGb 761; 25 patients received an oral daily
dose of donepezil 5mg; and remaining 26 patients took
a placebo. The primary outcome measures were MMSE
(mini-mental state examination), SKT and Clinical Global
Impression (CGI). The study found that both G. biloba and
donepezilweremoreeﬀectivethantheplaceboforimproving
the cognitive function in patients with mild to moderate
AD according to the measures of SKT and CGI (but not
of MMSE), and the diﬀerences were statistically signiﬁcant;
however, there was no statistical diﬀerence between G. biloba
and donepezil based on all three measures. In addition,
there were no major side eﬀects reported. Thus, this study
concluded that G. biloba could be a valuable alternative to
cholinesteraseinhibitorsforthetreatmentofAD.Thequality
of the study was rated high with sound randomization
and blinding procedures and a detailed dropout follow-
up. The only concern is its small sample size, which may
limit its external validity (i.e., generalization to other clinical
settings).
3.2. Ginseng. Ginseng grows in Northeastern Asia. Ginseng
root has been used in folk medicine in countries like4 Evidence-Based Complementary and Alternative Medicine
Table 2: The mechanisms of action of single Chinese herbs in the treatment of AD.
Herb Mechanisms of actions
(i) Increase in cholinergic neuron function,
(ii) Protection against the Aβ protein induced oxidative damages (degrading hydrogen peroxide,
preventing lipid from oxidation and trapping reactive oxygen species),
G. biloba [20] (iii) Prevention of Aβ protein induced ﬁbrillogenesis as well as the formation ADDLs,
(iv) Inhibition of cholesterol-induced overproduction of APP,
(v) Anti-apoptosis (opposing mitochondria-initiated apoptosis, downgrading caspase-12,
upgrading BCL2),
(vi) Regulation of gene expression
(i) Protection against the Aβ protein and hydrogen peroxide induced oxidative damages
(ii) Anti-apoptosis (regulating gene expression: Bcl-2, Bax, P53 and caspase-3),
(iii) Modulating secretary APP and protein kinase C-α,
Huperzine A [21, 22] (iv) Protection against hypoxia, ischemia and glutamate induced brain injury and cytotoxiicity,
(v) Antagonizing eﬀects on NMDA (N-methyl-D-aspartate) receptors,
(vi) Regulation of the expression and secretion of nerve growth factor and its signaling
Uncaria rhynchophylla [23] (i) Inhibition of aggregation of Aβ protein,
(ii) Destabilization of preformed Aβ neuroﬁbrills
(i) Increase in the uptake of choline in central nervous system,
(ii) Release of acetylcholine from hippocampus,
Ginseng [19]
(iii) Increase in choline acetyltransferase,
(iv) Protection against the Aβ protein induced neurotoxic eﬀects,
(v) Repair of Aβ-damaged neuron networks,
(vi) Reducing the level of Aβ
Tenuigenin (P. tenuifolta)[ 24] (i) Decrease of the secretion of Aβ protein via BACE1 (β-secretase) inhibition
(i) Alteration of the processing of amyloidal precursor protein,
Berberine (C. rhizoma)[ 25, 26] (ii) Decrease of the secretion of Aβ protein,
(iii) Acetylcholinesterase inhibitory activity
Indirubins [27] (i) Inhibition of abnormal tau phosphorylation by inhibiting glycogen synthase kinase-3 beta and
CDK5/p25
China and Korea for boosting Qi (energy). It is used as an
adaptogen or aphrodisiac, and can be applied to patients
with low energy, immune weakness and sexual dysfunction.
Research has suggested that ginseng is able to enhance
psychomotorandcognitiveperformance,andcanbeneﬁtAD
by improving brain cholinergic function, reducing the level
of Aβ, and repairing damaged neuronal networks [19, 28].
Ginseng as an adjuvant treatment in patients with AD
was analyzed in a clinical study conducted by Heo et al. [19].
Korean Ginseng used in the study is in principle similar to
Chinese ginseng. The study recruited patients aged 50 years
or older with mild to moderate AD dementia, but patients
with a history of psychiatric or neurological disorders were
excluded. All patients included in the study had been treated
withwesternmedicationsusedforADforatleastsixmonths.
The study design was an open-label RCT. Sixty-one patients
were randomized into three groups. Fifteen patients received
an oral daily dose of 9g ginseng, 15 patients received an
oral daily dose of 4.5g ginseng and 31 patients took a
placebo. The active constituents of ginseng used in this study
are ginsenosides composed of Rb1 (1.96%), Rb2 (2.18%),
Rc (1.47%), Rd (0.72%), Re (1.11%), Rf (0.24%), Rg1
(0.49%), Rg2 (0.13%), Rg3 (0.12%), Rh1 (0.12%) and Rh2
(0.003%). During the 12-week study period, anti-dementia
medications used before the study were continued. The
primary outcome measures were ADAS, Korean version of
MMSE,andClinicalDementiaRating(CDR).Thehigh-dose
ginseng group showed statistically signiﬁcant improvement
on the ADAS and CDR (but not MMSE) at the end of the
study, when compared with the control group. However,
such improvement was not observed in the low-dose ginseng
group. This study was poorly designed with an insuﬃcient
description of randomization and without blinding. Fur-
thermore, the sample size was small, and there was also the
confoundingeﬀectduetoconcurrentlyadministeredwestern
medications.
3.3. Huperzine A. Huperzine A is an alkaloid extracted from
the Chinese herb Lycopodium serratum and used in Chinese
folk medicine for the treatment of trauma, strains, swelling,
schizophrenia, and so forth. [21] .T h eh e r bi sap o t e n t ,
reversible and selective inhibitor of acetylcholinesterase,
which activity is even stronger than galantamine [12], an
FDA-approved drug for the treatment of mild to moderate
AD and other memory disorders. As the decline in brain
cholinergic function is a major factor responsible for theEvidence-Based Complementary and Alternative Medicine 5
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Figure 1: Neuronal changes in the Alzheimer’s brain. In the early stage (a), there are amyloidal deposits surrounding neurons and formation
of neuroﬁbrillary tangles in the neuron. In the next stage (b), amyloidal deposits cause inﬂammation and damage due to oxidative stress
in the brain. In the late stage (c), neurons degenerate in the process known as apoptosis and neurotransmitters dysfunction, resulting in
dementia.
memory deﬁcit in AD, Huperzine A has emerged as a
promising candidate for the treatment of AD patients. Other
potentially beneﬁcial eﬀe c t s ,a sf a ra sA Di sc o n c e r n e d ,
include modiﬁcation of APP processing, protection against
Aβ-induced oxidative injury and neuronal apoptosis, regu-
lation of nerve growth factor and reduction in glutamate-
induced toxicity [21, 22].
Huperzine A has shown promise for AD, as indicated by
in vitro experiments and animal models. Clinical trials have
been conducted in China to determine its eﬃcacy on the
disease, but only two studies were published in the English
literature [17, 18]. On the basis of the evidence presented
in the six trials conducted in China and published in the
Chinese literature, a systematic review found that Huperzine
A had some beneﬁcial eﬀects and no serious adverse eﬀects
for patients with AD [29]. Among the four trials considered
in one analysis based on the measure of MMSE, two trials
producedstatisticallysigniﬁcantresultsinfavorofHuperzine
A over placebo, two showed no statistical diﬀerence between
the herb and placebo, but combining evidence quantitatively
yielded a positive result. In terms of the measure of ADAS-
cog, a single trials with more than 200 patients found that
Huperzine A was superior to placebo statistically. Taken
together, only one study [18] was of adequate quality and
sample size, and the overall evidence was inadequate to
support its clinical use at present. More high-quality large-
scale RCTs are needed for further determination of its
eﬃcacy.
3.4. Other Promising Herbs. The Chinese herb Uncaria rhyn-
chophylla is used for the treatment of headache, convulsion
and hypertension in Chinese medicine. It is a potentially
novel therapeutic agent to prevent or treat AD because it has
potent inhibitory eﬀects on ﬁbril formation of Aβ and can
also destabilize preformed Aβ ﬁbrils [23].
Tenuigenin is a compound extracted from the Chinese
herb Polygala tenuifolta, which exhibits the property of
soothing the mind and is indicated for insomnia, mental
confusion and disorientation in Chinese medicine. Research
has found that tenuigenin can inhibit the secretion of Aβ
in cultured cells, which may explain its ability to improve
cholinergic function degraded through Aβ in rat models
[24].
Berberine is an alkaloid isolated from the Chinese
herb Coptidis rhizome. The herb has been used in folk
medicine because of its antidiarrheal, antimicrobial and
anti-inﬂammatory properties. Research ﬁndings indicate
that berberine can reduce Aβ secretion by altering APP
processing in a way to shift from the amyloidogenic to non-
amyloidogenic pathway [26].
Indirubin is an active ingredient of a Chinese herbal
formula, Danggui Longhui Wan, used in the treatment of
c h r o n i cd i s e a s e ss u c ha sl e u k e m i a .I t sp o t e n t i a lv a l u ei n
the treatment of AD patients is attributable to its property
of inhibiting two protein kinases involved in abnormal tau
phosphorylation in AD [27].6 Evidence-Based Complementary and Alternative Medicine
Alzheimer’s disease pathogenesis and
herbal mechanisms
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Figure 2: The blocking sites of herbs on the pathogenesis of Alzheimer’s disease. Ginkgo biloba: B, D–G; Huperzine A: B, D, F, G; Uncaria
rhynchophylla: B, E; Ginseng: B, F, G; Tenuigenin (Polygala tenuifolta): B; Berberine (Coptidis rhizoma): B, C, G; Indirubins: A.
4. Discussion
AD is a progressive neurodegenerative disorder. In light
of the limited eﬀectiveness and potential side eﬀects of
the current AD medications, there is increasing interest in
using herbal medicine as an alternative or complementary
therapy for AD. Chinese herbs are particularly promising, as
they dominate the herbs that have undergone clinical trials.
However, these Chinese herbs, as included in previous sys-
tematic reviews [11, 12], are mostly in the form of formulas
rather than single herbs. From the scientiﬁc standpoint, it
is important to understand the pharmacological property of
a single herb and its active chemical ingredients. However,
formula validation leaves no clue as to what the active herbal
componentsareintheformula,howtheyinteract,andwhich
herbs should be blamed for an adverse reaction if it happens.
The present review distinguishes from other related reviews
by focusing on single Chinese herbs and examining their
eﬀects on the pathophysiology of AD.
The results of the three RCTs assessing the eﬃcacy of
G. biloba in AD are mixed. More speciﬁcally, the studies
conducted by Maurer et al. [14] and Mazza et al. [16]f o u n d
statistically signiﬁcant diﬀerences in favor of the herbal
intervention over the placebo control, whereas the study
conducted by Schneider et al. [15] showed no signiﬁcance
diﬀerences between the herbal and control groups. However,
the Schneider’s study would have more impact than the
other two studies in terms of the sample size and quality of
study. Further observation indicated that the inconsistency
among these studies could be due to the diﬀerence in the
chosen outcome measures. Two studies [14, 16] with positive
conclusions for the herbal intervention used the SKT test,
while the third study [15] with a negative conclusion used
the ADAS-cog scale. The SKT test is designed to assess the
deﬁcits of memory and attention, while ADAS-cog measures
the disturbances of memory, language, praxis, attention and
other cognitive abilities that are often referred to as the core
symptoms of AD [30]. ADAS-cog involves more diﬃcult
cognitive tasks than SKT in our opinion. Accordingly, the
evidence based on the three studies, if viewed together
consistently, would indicate that G. biloba improves the
cognitive function of AD patients at the level measurable
by SKT but not to the level measurable by ADAS-cog.
The results illustrate the importance in the choice of the
primary outcome measure in the study design. The ﬁnal
interpretation of a trial outcome has to take this factor into
account. The eﬃcacy and safety of G. biloba in AD will be
further determined by a number of ongoing RCTs registered
in the National Institute of Health registry of clinical trials.
Currently FDA-approved medications for AD such as
acetylcholinesterase inhibitors improve cognitive function
but do not treat the cause of the disease characterized
by the deposition of amyloid plaques and formation of
neuroﬁbrillary tangles. On the other hand, the Chinese
herbs, as analyzed in the present review, addressed the
fundamentalmechanisms ofAD one wayor another (Table 2
andFigure 2)incontrasttowesternherbssuchasS.oﬃcinalis
and M. oﬃcinalis.
Neuroprotectivity from amyloid insults on neurons has
been assessed for various herbs (Figure 3). As research
indicates that the deposition of amyloid plaques alone does
not account for the entire degenerative process of AD [6],
the theory based on neuroﬁbrillary tangles may oﬀer a
more plausible explanation about its pathophysiology. To
date, it is not clear yet whether and to what extent herbal
medicine can reverse the progressive course of the disease by
resolving amyloid plaques or neuroﬁbrillary tangles, despite
that some cognitive beneﬁts from clinical studies have been
demonstrated. The eﬃcacy of medical or herbal treatment
was assessed on mild to moderate AD patients in the clinicalEvidence-Based Complementary and Alternative Medicine 7
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Figure 3: Neuroprotectivity against amyloid protein based on the
s t u d yb yK i me ta l .[ 31]. 1, Cinnamomum cassia;2 ,Curcuma
aromatica;3 ,Gastrodia elata;4 ,G. biloba;5 ,Inula helenium;6 ,
Polygonatum sp.; 7, Scutellaria baicalensis;8 ,Zingiber oﬃcinale;
EC50:Concentrationtoachieve50%cell(primaryneuron)viability.
trials conducted to date. It makes sense to test herbal
neuroprotectivity on mild AD cases for stopping disease
progression in future clinical trials.
5. Conclusion
Chinese herbs show promise in AD treatment because
of their cognitive beneﬁts and more importantly, their
mechanisms of action with respect to the fundamental
pathophysiology of the disease. However, most of the clinical
studies in previous reviews used herbal formulas rather
than single herbs. Our review here has identiﬁed seven
single Chinese herbs with potential therapeutic eﬀects for
AD. Among them, G. biloba, Huperzine A (Lycopodium
serratum), and Ginseng have been assessed for their clinical
eﬃcacyseparatelyinsixrandomizedcontrolledclinicaltrials.
Nonetheless, our review here has found that the current
clinical evidence in support of the use of Chinese herbs in
AD is still inconclusive or inadequate. However, no serious
adverse events were reported. The data from other high-
quality, large-sample RCTs currently underway are expected
toprovidefurtherevidencefortheclinicaleﬃcacyofChinese
herbal medicine in AD treatment. Moreover, the future
direction should emphasize the trial of new herbs that are
potentially eﬀective in treating the root of the disease.
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